Clinical trial · Interventional
Effect of Hypoxia on FMISO PET to Response to Lu-177 PSMA Treatment
Effect of 18F-Fluoromisonidazole (18F-FMISO) PET Imaging on Evaluation of Hypoxia Before Lu-177 PSMA Treatment for Prostate Cancer
NCT06433063CI-TRIAL-00077527LuMISOunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It is aimed to evaluate hypoxia before Lu-177 PSMA treatment in prostate cancer and to show its effect on treatment success with 18F-FMISO PET imaging, which allows in-vivo evaluation and quantification of tumor hypoxia, which is known to be one of the factors affecting radiotherapy resistance.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hypoxia | — | UNRESOLVED | — |
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| F-MISO PET | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment arm
- description
- Patients who underwent FMISO PET imaging before Lu-177 PSMA radionuclide treatment for CRPC
- interventionNames
- Diagnostic Test: F-MISO PET
Primary outcomes (3)
- measure
- To evaluate tumor hypoxia with F-MISO PET to PSA response
- timeFrame
- 6. month after radionuclide treatment
- description
- Evaluation of the effect of tumor hypoxia to PSA response after Lu-177 PSMA treatment
- measure
- To evaluate tumor hypoxia with F-MISO PET to radiological response
- timeFrame
- 6. month after radionuclide treatment
- description
- Evaluation of the effect of tumor hypoxia to radiological response with RECIST criteria after Lu-177 PSMA treatment
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * over 18 years old * Patients diagnosed with prostate cancer who were referred to our clinic for Lu-177 PSMA treatment and were found suitable for treatment Exclusion Criteria: * Has a life expectancy of less than 3 months * ECOG\>2 * contraindication for radionuclide treatment with Lu-177 PSMA
References
Publications (0)
Data not yet available
No reference posted for this study.